Functional mapping of factor VIII C2 domain

Thrombosis and Haemostasis

Volumn 106, Issue 1, 2011, Pages 121-131

  Pellequer, Jean Luc ^a   Chen, Shu Wen W ^a   Saboulard, Didier ^b   Delcourt, Marc ^b   Négrier, Claude ^c   Plantier, Jean Luc ^c  

^a DIF   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Global Bioenergies   (France)

Author keywords

Coagulation factors; Factor viii; Protein structure folding

Indexed keywords

ALANINE; ANTIGEN; BLOOD CLOTTING FACTOR 8; GLYCINE; PROCOAGULANT; SERINE;

ARTICLE; BETA SHEET; CELL STRAIN COS1; COMPUTER MODEL; CONTROLLED STUDY; GENETIC TRANSFECTION; MUTANT; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

EID: 79960065995     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-09-0572     Document Type: Article

References (47)

1. Fay PJ, et al. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-2177.
2. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 1988; 85: 2429-2433.
3. van Dieijen G, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
4. Gitschier J, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
5. Toole JJ, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
6. Ngo JC, et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008; 16: 597-606.
7. Pratt KP, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-442.
8. Shen BW, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-1247.
9. Foster PA, et al. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
10. Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995; 270: 13826-13833.
11. Kuwabara I, et al. Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods 1999; 224: 89-99.
12. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-563.
13. Saboulard D, et al. High-throughput site-directed mutagenesis using oligonucleotides synthesized on DNA chips. Biotechniques 2005; 39: 363-368.
14. Brünger AT. X-PLOR, version 3.1. A system for X-ray crystallography and NMR. Yale University Press, New Haven, (CT); 1992.
15. MacKerell AD, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
16. Pellequer J-L, Chen S-W. Multi-template approach to modeling engineered disulfide bonds. Proteins 2006; 65: 192-202.
17. Chen S-WW, Pellequer JL. Identification of functionally important residues in proteins using comparative models. Curr Med Chem 2004; 11: 595-605.
18. Pellequer JL, Westhof E. PREDITOP: a program for antigenicity predictions. J Mol Graph 1993; 11: 204-210.
19. Odorico M, Pellequer J-L. BEPITOPE: predicting the location of continuous epitopes and patterns in proteins. J Mol Recognit 2003; 16: 20-22.
20. Pellequer JL, et al. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis 1998; 24: 448-461.
21. Meeks SL, et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
22. Nagashima M, et al. Alanine-scanning mutagenesis of the epidermal growth factor- like domains of human thrombomodulin identifies critical residues for its cofactor activity. J Biol Chem 1993; 268: 2888-2892.
23. Dimitrov JD, et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 2010; 115: 2682-2685.
24. Spiegel PC, et al. Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279: 53691-53698.
25. Lewis DA, et al. Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost 2003; 89: 795-802.
26. Pipe SW, Kaufman RJ. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996; 271: 25671-25676.
27. Schatz SM, et al. Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein. Br J Haematol 2004; 125: 629-637.
28. Gilbert GE, et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-6381.
29. Chen L, et al. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther 2007; 15: 1856-1862.
30. Webb E, et al. Enhanced secretory ability for the human factor VIII light chain produced in baculovirus-infected insect cells. Cytotechnology 1996; 21: 165-170.
31. Takeshima K, et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 788-794.
32. Healey JF, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-3709.
33. Scandella D, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819.
34. Shima M, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
35. Nogami K, et al. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain. Int J Hematol 2007; 85: 317-322.
36. Lewis DA, et al. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. Blood Coagul Fibrinolysis 2003; 14: 361-368.
37. d'Oiron R, et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004; 103: 155-157.
38. Liu Z, et al. Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding. J Biol Chem 2010; 285: 8824-8829.
39. Gale AJ, et al. Structural basis for hemophilia A caused by mutations in the C domains of blood coagulation factor VIII. Thromb Haemost 2000; 83: 78-85.
40. Lewis DA, et al. Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. Thromb Haemost 2005; 93: 833-841.
41. Nogami K, et al. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol 1999; 107: 196-203.
42. Spiegel PC, Jr., et al. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-19.
43. Parker ET, et al. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 2004; 104: 704-710.
44. Merritt EA, Bacon DJ. Raster3D: Photorealistic molecular graphics. Meth Enzymol 1997; 277: 505-524.
45. Humphrey W, et al. VMD: visual molecular dynamics. J Mol Graph 1996; 14: 33-38.
46. Chen S-wW, et al. Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr Med Chem 2009; 16: 953-964.
47. Frishman D, Argos P. Knowledge-based protein secondary structure assignment. Proteins 1995; 23: 566-579.